Real-World Effectiveness and Patient-Reported Outcomes of Xeligekimab in Moderate-to-Severe Plaque Psoriasis With Challenging Clinical Profiles: A Prospective, Multicenter, Observational Study in China (XP-Real) (EADV 2026) - Aug 6, 2026 - Abstract #P1151; AS-3024; Pres time: Sep 30, 2026; Location: ePoster Area; P | "Missing data were handled using multiple imputation (MI; m=40). PASI, Psoriasis Area and Se·verity Index; PGA, Physician's Global Assessment; DLQI, Dermatology Life Quality Index; NRS, Numerical Rating Scale; PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalized Anxiety Disorder 7-item scale."
Clinical • Observational data • Patient reported outcomes • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Depression • Dermatology • General Anxiety Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Mood Disorders • Plaque Psoriasis • Pruritus • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Seronegative Spondyloarthropathies • IL17A
|
|
Yehong Kuang 1; Xincai Xiong 2; Xiuzu Song 3; Tianhong Xu 3; Nan Yu 4; Xuesong Yang 5; Cuihong Lian 6; Wei Min 7; Yongxin Sun 8; Jialin Wang 9; Shanshan Li 10; Yanling Li 11; Liangjuan Ma 12; Fuguang Zuo 13; Naihui Zhou 14; Rui-Li Zhang 15; Wenjun Zheng 16; Yanhua Liang 17; Lei Nie 18; Yuzhen Li 19; Yong Zhang 20; LAN CHEN 20; Shaojie Chen 21; Furen Zhang 22; Jianyun Lu 23; Zudong Meng 24; Huiping WANG 25; Xiaodong Li 26; Juanli Fan 27; bingjiang Lin 28; Mingkai Ji 29; Shuanglin Cao 30; Yu Gong 31; Chengzhi Lv 32; Haiying Wang 33; Sheng Wei 34; han ma 35; Yunfeng Hu 36; Lingang Liu 37; Yuanmin He 38; Cheng Zhou 39; Shuping Guo 40; Mengjiao Wang 41; JIEJIE LU 42; Na Zhang 43; Zhikai Hu 44; Juan Su 1; Xiang Chen 1
|